Review
Oncology
Pawel Szponar, Piotr Petrasz, Katarzyna Brzezniakiewicz-Janus, Tomasz Drewa, Piotr Zorga, Jan Adamowicz
Summary: This study reviewed and summarized the literature on therapeutic isotopes specific for PSMA, and found that Lu-177-PSMA-617 has promising outcomes in treatment.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Sahithi Pamarthy, Hatem E. Sabaawy
Summary: Advancements in utilizing patient derived organoids (PDOs) for modeling prostate cancer have shown promise in predicting therapeutic responses and screening effective targeted therapies. Technological innovations in generating PDOs and incorporating various extracellular matrices have improved the accuracy and reliability of these models. PDOs, especially those derived from single cells, accurately represent the molecular features of the original tumor and serve as a reliable pre-clinical model for understanding individual tumors and designing tailored targeted therapies.
Review
Pharmacology & Pharmacy
Tyrillshall S. T. Damiana, Simone U. Dalm
Summary: Radionuclide therapy and targeted radionuclide therapy have gained interest in cancer treatment, but only a small percentage of patients achieve complete response. Therefore, combining these treatments with other anti-cancer therapies may be a promising strategy to improve outcomes.
Review
Pharmacology & Pharmacy
Anusha Muralidhar, Hemanth K. Potluri, Tanya Jaiswal, Douglas G. McNeel
Summary: Prostate cancer is the most diagnosed malignancy in men in the United States, but targeted radionuclide therapies have shown promise in improving patient outcomes. While immune-based treatments have generally had limited success, radiation therapy may be able to combine with immunotherapy to more effectively eliminate metastases. This review provides an overview of targeted radiation agents approved for prostate cancer and explores their potential combination with immunotherapy.
Article
Biochemistry & Molecular Biology
Sreeja Sreekumar, Dong Zhou, Cedric Mpoy, Elsa Schenk, Jalen Scott, Jeffrey M. Arbeit, Jinbin Xu, Buck E. Rogers
Summary: This study identified PARP-1 as an attractive target for therapeutic strategies in advanced prostate cancer. Synthesized radio-brominated Auger emitting inhibitor, [Br-77]Br-WC-DZ, induced DNA damage, cell cycle arrest, and cytotoxicity in prostate cancer cells. The findings provide a strong rationale for future clinical investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Vittoria Rago, Anna Perri, Silvia Di Agostino
Summary: One of the major goals in cancer research is to develop new anticancer therapies. Preclinical in vitro models, such as patient-derived xenograft (PDX) models and cultured organoids derived from patients (PDO), have become indispensable tools for understanding cancer progression, drug resistance, and metastasis. This article reviews studies from the past 10 years on the use of PDX models and PDOs in studying prostate cancer, which is characterized by genomic instability and resistance to conventional therapies. The limitations and new challenges in using these models for drug testing and developing molecular therapies are also discussed.
Review
Oncology
Ephraim E. Parent, Adam M. Kase
Summary: This review explores the use of targeted radionuclide therapy in the treatment of metastatic prostate cancer. Lu-177 PSMA-617 and (RaCl2)-Ra-223 are commonly used therapies, but there is a lack of guidance on how to best utilize these treatments. The article also introduces other less well-known targeted radionuclide therapies.
Article
Oncology
Bhavneet Bhinder, Alison Ferguson, Michael Sigouros, Manik Uppal, Ahmed G. Elsaeed, Rohan Bareja, Hussein Alnajar, Kenneth Wha Eng, Vincenza Conteduca, Andrea Sboner, Juan Miguel Mosquera, Olivier Elemento, Himisha Beltran
Summary: This study analyzed the RNA-sequencing and whole-exome sequencing data of 170 patients with neuroendocrine prostate cancer (NEPC). It found that NEPC has a unique tumor immune landscape compared to other prostate cancer types and small-cell lung cancer (SCLC). NEPC is characterized by a relatively immune-depleted tumor immune microenvironment and less mutations, but has comparable expression of checkpoint genes PD-L1 and CTLA-4 with SCLC. These findings can inform the development of immunotherapy strategies for NEPC.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Joshua A. Korsen, Julia A. Gutierrez, Kathryn M. Tully, Lukas M. Carter, Zachary Samuels, Samantha Khitrov, John T. Poirier, Charles M. Rudin, Yu Chen, Michael J. Morris, Lisa Bodei, Nagavarakishore Pillarsetty, Jason S. Lewis
Summary: This study developed and evaluated a Lu-177-labeled DLL3-targeting antibody SC16 (Lu-177-DTPA-SC16) as a treatment for NEPC. The drug showed high tumor uptake and specificity in in vivo experiments, and demonstrated dose-dependent therapeutic efficacy and safety in mouse models.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Mingchen Shi, Yu Wang, Dong Lin, Yuzhuo Wang
Summary: Patient-derived xenografts (PDXs) have gained significant attention in cancer research as relevant models due to their retention of histopathological and molecular heterogeneity from donor tumors. Neuroendocrine prostate cancer (NEPC) PDX models are increasingly being generated and have shown utility in various research applications. This review provides a comprehensive overview of NEPC PDX collections, highlighting their potential for identifying therapeutic targets and evaluating drug responses.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lisa M. Gudenkauf, Melody N. Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I. Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R. Armstrong, Khaled Komrokji, Laura B. Oswald, Heather S. L. Jim, Ghassan El-Haddad, Wolfgang P. Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez
Summary: This article introduces the development of the first patient-reported outcome (PRO) measure, called Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT), for prostate cancer patients receiving radionuclide therapy (RNT). The measure, consisting of 15 items, was refined through multiple steps involving the review of published trials, interviews with patients, caregivers, and clinicians, and input from experts. It is considered to be a relevant and useful tool for monitoring symptoms and toxicities in clinical trials and real-world settings.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Oncology
Claudia Mosillo, Maria Letizia Calandrella, Claudia Caserta, Serena Macrini, Annalisa Guida, Grazia Sirgiovanni, Sergio Bracarda
Summary: This review summarizes and discusses new therapeutic approaches for metastatic castration-resistant prostate cancer, including the prognostic and predictive role of molecular alterations, investigation techniques, and potential clinical implications. Despite the approval of several drugs, metastatic castration-resistant prostate cancer remains a lethal disease.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Qiaoqiao Shu, Xianjun Li, Xi Chen, Yue Chen, Liang Cai
Summary: An 84-year-old man with prostate cancer underwent PET/CT for staging, which showed no significant abnormal tracer accumulation in Ga-68-prostate-specific membrane antigen PET/CT but elevated tracer uptake in F-18-OC (F-18-AlF-NOTA-octreotide) PET/CT at multiple sites. The patient chose to receive 1 cycle of Lu-177-DOTATATE peptide receptor radionuclide therapy and experienced radiographic tumor remission and improvement of clinical symptoms after just one cycle of treatment.
CLINICAL NUCLEAR MEDICINE
(2023)
Review
Biology
Luca Filippi, Barbara Palumbo, Oreste Bagni, Viviana Frantellizzi, Giuseppe De Vincentis, Orazio Schillaci
Summary: The aim of this review is to evaluate the impact of DNA damage repair (DDR) mutations on the response and outcomes of advanced prostate cancer (PCa) patients undergoing radionuclide therapies. A systematic literature search was conducted using two main databases based on PRISMA criteria. Seven studies involving 326 patients, of whom 201 (61.6%) had DDR defects, were selected. The majority of the selected studies were retrospective, and a trend towards longer survival in PCa patients with DDR defects undergoing radionuclide targeted therapy with alpha emitters was observed, although more research is needed to confirm these findings.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ruping Li, Huihui He, Xinling Li, Xiaobin Zheng, Zhijian Li, Hu Zhang, Jiacong Ye, Weiguang Zhang, Chunjing Yu, Guokai Feng, Wei Fan
Summary: In this study, a high-affinity EDB-FN targeted peptide named EDBp was identified and three probes based on EDBp were developed for surgical navigation, radionuclide imaging, and therapy of thyroid cancer. The results from animal experiments and clinical evaluations demonstrated the potential application of these probes in the diagnosis and treatment of thyroid cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Veterinary Sciences
Veerle Kersemans, Sheena Wallington, Philip D. Allen, Stuart Gilchrist, Paul Kinchesh, Richard Browning, Katherine A. Vallis, Kathrin Schilling, Phil Holdship, Lee-Anne Stork, Sean Smart
LABORATORY ANIMALS
(2020)
Article
Oncology
Aurelien Corroyer-Dulmont, Samuel Valable, Nadia Falzone, Anne-Marie Frelin-Labalme, Ole Tietz, Jerome Toutain, Manuel Sarmiento Soto, Didier Divoux Laurent Chazalviel, Elodie A. Peres, Nicola R. Sibson, Katherine A. Vallis, Myriam Bernaudin
Article
Oncology
S. Teoh, F. Fiorini, B. George, K. A. Vallis, F. Van den Heuvel
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Suliana Teoh, Francesca Fiorini, Ben George, Katherine A. Vallis, Frank Van den Heuvel
BRITISH JOURNAL OF RADIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Farasat Kazmi, Katherine A. Vallis, Balamurugan A. Vellayappan, Aishwarya Bandla, Duan Yukun, Robert Carlisle
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Chemistry, Multidisciplinary
Joshua Owen, Eloise Thomas, Jyothi Menon, Michael Gray, Irini Skaripa-Koukelli, Martin R. Gill, Sheena Wallington, Rebecca L. Miller, Katherine A. Vallis, Robert Carlisle
JOURNAL OF CONTROLLED RELEASE
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Edward O'Neill, Veerle Kersemans, P. Danny Allen, Samantha Y. A. Terry, Julia Baguna Torres, Michael Mosley, Sean Smart, Boon Quan Lee, Nadia Falzone, Katherine A. Vallis, Mark W. Konijnenberg, Marion de Jong, Julie Nonnekens, Bart Cornelissen
JOURNAL OF NUCLEAR MEDICINE
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Anne-Marie Frelin-Labalme, Thomas Roger, Nadia Falzone, Boon Quan Lee, Nicola R. Sibson, Katherine A. Vallis, Myriam Bernaudin, Samuel Valable, Aurelien Corroyer-Dulmont
Article
Radiology, Nuclear Medicine & Medical Imaging
Maxime Chauvin, Damian Borys, Francesca Botta, Pawel Bzowski, Jeremie Dabin, Ana M. Denis-Bacelar, Aurelie Desbree, Nadia Falzone, Boon Quan Lee, Andrea Mairani, Alessandra Malaroda, Gilles Mathieu, Erin McKay, Erick Mora-Ramirez, Andrew P. Robinson, David Sarrut, Lara Struelens, Alex Vergara Gil, Manuel Bardies
JOURNAL OF NUCLEAR MEDICINE
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elliot M. Abbott, Nadia Falzone, Boon Q. Lee, Christiana Kartsonaki, Helen Winter, Tessa A. Greenhalgh, Daniel R. McGowan, Nigar Syed, Ana M. Denis-Bacelar, Philip Boardman, Ricky A. Sharma, Katherine A. Vallis
JOURNAL OF NUCLEAR MEDICINE
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael J. Trimpl, Djamal Boukerroui, Eleanor P. J. Stride, Katherine A. Vallis, Mark J. Gooding
Summary: A deep learning approach was investigated for 3D segmentation of anatomical structures based on user-provided 2D contours, improving delineation times and contouring consistency. By training models on a diverse set of structures and expanding the training set, segmentation performance for both seen and unseen structures was enhanced. Incorporating contextual information into deep learning models enables generalization and prediction for structures not represented in the training set, facilitating semi-automatic segmentation of CT images.
Editorial Material
Biology
Katherine A. Vallis, Roger F. Martin, Nadia Falzone
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Rajeshwari Tiwari, Prashant S. Shinde, Sreejesh Sreedharan, Anik Kumar Dey, Katherine A. Vallis, Santosh B. Mhaske, Sumit Kumar Pramanik, Amitava Das
Summary: This study demonstrates a proof of concept for a light-activatable prodrug with desired organelle specificity, aiming to address the issues of drug specificity and systemic toxicity of traditional anticancer drugs.
Article
Oncology
Elliot Abbott, Robert Steve Young, Caroline Hale, Kimberly Mitchell, Nadia Falzone, Katherine A. Vallis, Andrew Kennedy
Summary: A dosimetric framework for combining SIRT and EBRT was established based on clinical experience in patients with hepatocellular carcinoma, showing no major toxicity in the combined treatment. A radiobiological modeling framework was developed to manage the combined treatments, and inverse dose planning of EBRT after SIRT could provide improved dose distributions and flexibility to the clinical workflow, further research is needed through prospective trials.
ADVANCES IN RADIATION ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Martin R. Gill, Michael G. Walker, Sarah Able, Ole Tietz, Abirami Lakshminarayanan, Rachel Anderson, Rod Chalk, Afaf H. El-Sagheer, Tom Brown, Jim A. Thomas, Katherine A. Vallis
